REG-4basebio Plc: Research Collaboration

4BasebioAnnouncement

10/06/2022 07:15

10 June 2022

4basebio PLC

("4basebio", the "Company" or the “Group”)

Research Collaboration
for treatment of Neurofibromatosis Type 1

4basebio PLC (AIM: 4BB), the Cambridge based life sciences group focused on
the development of synthetic DNA and non-viral vectors for use in the field of
cell and gene therapies and vaccines, is pleased to announce its collaboration
with University of Alabama (“UA”) and Teesside University (“TU”) in a
research project aimed at developing an effective treatment for
Neurofibromatosis Type 1 (NF1).

The universities have been awarded almost $1million from the US based Gilbert
Family Foundation to fund a three-year research program aimed at developing a
life-changing gene therapy with applicability to all NF1 patients and which
will use a non-viral vector for targeted delivery of full length NF1 DNA. 4BB
will support this project by designing and developing a 4BB non-viral
Hermes™ vector and 4BB hpDNA™ sequence as payload for UA and TU.

NF1 is a genetic condition which causes usually benign tumours to develop
anywhere in the nervous system, including the brain, spinal cord and nerves. 
Complications of NF1 are many and can include learning difficulties, speech
difficulties and skeletal malformations, heart and blood vessel
(cardiovascular) problems, loss of vision, and severe pain.  NF1 is caused by
mutations in the NF1 gene which regulates the production of neurofibromin
protein.

Dr Heikki Lanckriet, CEO and CSO for 4basebio said: “We are very pleased to
be able to support this research project and are delighted that this exciting
collaboration between academia and industry has been recognised with the award
from the Gilbert Family Foundation.”

Dr Deeann Wallis, PI at University of Alabama, said: “I’m excited about
partnering with 4basebio and utilizing both their non-viral Hermes™ vector
and hpDNA™ sequence as payload to target delivery of NF1 as a therapeutic
for those with Neurofibromatosis Type I.  Such a combination of technologies
is an attractive therapeutic approach for individuals with few options.”

Dr Linda Popplewell, Professor of Genetic Medicine at National Horizon Centre,
Teesside University, said ‘The opportunity to work with 4basebio on this
Gilbert Family Foundation GTi award is exceptionally exciting. Access to their
impressive technologies and their application to NF1 has the potential to be
transformative”.

For further enquiries, please contact:

4basebio PLC                     
                               +44 (0)12 2396
7943

Heikki Lanckriet

Nominated Adviser           
                                     +44
(0)20 7213 0880

Cairn Financial Advisers LLP

Jo Tuner / Sandy Jamieson

Broker                                 
                              +44 (0)20 7220 0500

finnCap Ltd

Geoff Nash/Richard Chambers/Charlotte Sutcliffe

Notes to Editors

4basebio (AIM: 4BB) is a specialist life sciences group focused on therapeutic
DNA for cell and gene therapies and DNA vaccines and providing solutions for
effective and safe delivery of these DNA based products to patients. It is the
intention of the Company to become a market leader in the manufacture and
supply of high purity, synthetic DNA for research, therapeutic and
pharmacological use and develop non-viral vectors for the efficient delivery
of payloads. The immediate objectives of 4basebio are to continue the
validation of its DNA products and Hermes™ technology and commence revenue
generation during 2022. 4basebio also continues to advance its collaborations
to facilitate the functional validation of its DNA based products and cell and
gene delivery solutions.

Forward-looking statements

This announcement may contain certain statements about the future outlook for
the 4basebio.  Although the directors believe their expectations are based on
reasonable assumptions, any statements about future outlook may be influenced
by factors that could cause actual outcomes and results to be materially
different.



Copyright (c) 2022 PR Newswire Association,LLC. All Rights Reserved